BMRA — Biomerica Income Statement
0.000.00%
Last trade - 00:00- $8.04m
- $5.64m
- $5.31m
- 24
- 41
- 35
- 24
Annual income statement for Biomerica, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2021 May 31st | R2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.2 | 18.9 | 5.34 | 5.42 | 5.31 |
| Cost of Revenue | |||||
| Gross Profit | 0.366 | 2.98 | 0.446 | 0.611 | 0.498 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 14.7 | 23.4 | 12.6 | 11.8 | 10.4 |
| Operating Profit | -7.5 | -4.53 | -7.22 | -6.37 | -5.14 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.43 | -4.51 | -7.09 | -5.94 | -4.97 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.45 | -4.53 | -7.14 | -5.98 | -4.97 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.45 | -4.53 | -7.14 | -5.98 | -4.97 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.45 | -4.53 | -7.14 | -5.98 | -4.97 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.99 | -2.86 | -4.04 | -2.84 | -2.16 |